Arrowhead Research Corporation (ARWR)
Arrowhead Research Corporation, now known as Arrowhead Pharmaceuticals, specializes in the development of nucleic acid-based therapeutics, particularly RNA interference (RNAi) technologies. Founded in 1999, the company focuses on creating innovative treatments for various medical conditions, including rare diseases, viral infections, and metabolic disorders. It leverages its proprietary platform to design targeted and efficient gene-silencing therapies.
Company News
The article discusses the rare endocrinology and metabolic disorders market, focusing on hypophosphatasia, congenital adrenal hyperplasia, and severe hypertriglyceridemia. It highlights the challenges faced by patients, the current treatment landscape, and the pipeline of emerging therapies.
The Nasdaq 100 closed higher by around 0.2% on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company’s prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.
The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.